Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2009 by Oslo University Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00552526
First received: October 31, 2007
Last updated: March 18, 2009
Last verified: March 2009

October 31, 2007
March 18, 2009
November 2007
January 2011   (final data collection date for primary outcome measure)
Comparing amount of patients with 100%, >90% and >50% reduction in number of seizures between the two groups of seizures [ Time Frame: 4 months ] [ Designated as safety issue: No ]
Comparing amount of patients with 100%, >90% and >50% reduction in number of seizures between the two groups of seizures [ Time Frame: 4 months ]
Complete list of historical versions of study NCT00552526 on ClinicalTrials.gov Archive Site
  • Comparing the parents´evaluation of change in quality of life and cognitive function between the two groups. The parents will answer a questionary. [ Time Frame: Four months ] [ Designated as safety issue: No ]
  • Comparing side effects between the two groups [ Time Frame: Four months ] [ Designated as safety issue: Yes ]
  • Comparing change in slow activity and epileptic activity by template matching on 24 hour EEG [ Time Frame: Four months ] [ Designated as safety issue: No ]
  • Investigating side effects and change in number of seizures, change in EEG, quality of life and cognitive function after 13 months of treatment with the ketogenic diet [ Time Frame: 13 months ] [ Designated as safety issue: Yes ]
  • Is the effect of the ketogenic diet as good in children with severe mental retardation as in children with less severe learning disabilities? [ Time Frame: 4 and 12 months ] [ Designated as safety issue: No ]
  • Comparing the parents´evaluation of change in quality of life and cognitive function between the two groups. The parents will answer a questionary. [ Time Frame: Four months ]
  • Comparing side effects between the two groups [ Time Frame: Four months ]
  • Comparing change in slow activity and epileptic activity by template matching on 24 hour EEG [ Time Frame: Four months ]
  • Investigating side effects and change in number of seizures, change in EEG, quality of life and cognitive function after 13 months of treatment with the ketogenic diet [ Time Frame: 13 months ]
  • Is the effect of the ketogenic diet as good in children with severe mental retardation as in children with less severe learning disabilities? [ Time Frame: 4 and 12 months ]
Not Provided
Not Provided
 
Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy
Comparing Ketogenic Diet With the Most Appropriate Antiepileptic Drug- a Randomized Study of Children With Mental Retardation and Drug Resistant Epilepsy

This is an open randomized controlled study in children with mental retardation and refractory epilepsy in which treatment with ketogenic diet (KD) is compared with treatment with the antiepileptic drug (AED), not tried by the patient before, which we consider to be the most appropriate AED for the patient.

There are two trials in the study:

  • To compare the effect of the ketogenic diet with the effect of the most appropriate AED after 4 months
  • To evaluate the effect of the ketogenic diet after 4 and 13 months on the children who have been randomized to this treatment, the seizure frequency is compared with the frequency before start of treatment
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Epilepsy
  • Mental Retardation
  • Dietary Supplement: Ketogenic diet
    Ketogenic diet is a very strict high fat diet
  • Drug: Antiepileptic drug (AED)
    An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
  • Active Comparator: Ketogenic diet
    Intervention: Dietary Supplement: Ketogenic diet
  • Active Comparator: AED
    Most appropriate antiepileptic drug
    Intervention: Drug: Antiepileptic drug (AED)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
December 2013
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient is mentally retarded
  • The patient has tried at least 3 different AED:s including one combination with two or more different AED:s.
  • The parents are willing to include their child in the study after written and verbal information.
  • Patients with all types of epilepsy can be included.
  • The patient has at least 6 seizures/month.
  • The patient is submitted to our epilepsy center.
  • The seizures are possible to count
  • The patient has either generalized epilepsy, multifocal epilepsy or an epilepsy where it is undetermined whether it is localized or generalized such as Dravet syndrome classified as G40.3-G40.9 in ICD X.

Exclusion Criteria:

  • The family is expected to have compliance problems with treatment and/or seizure registration.
  • The hospital which have submitted the patient is not willing to accept the inpatient stays and the procedures that are necessary for the project.
  • The patient`s seizures are under acceptable control.
  • The patient has got a vagus nerve stimulator implanted within the last 18 months, has started a new antiepileptic drug within the last 2 months or has changed his antiepileptic drugs the last month.
  • The patient has a medical condition, for example a metabolic disease, where ketogenic diet is contraindicated.
  • The patient has a localized epilepsy classified as G40.0-G40.2 in ICD X.
  • The patient`s nutritional status is not good enough or intake of fluid is to small to permit treatment with ketogenic diet.
  • The patient has within the last 2 months been using medications or herbal medications that has a considerable effect on glucose metabolism, such as oral glucocorticoids.
  • The patient has within the last 2 months been using medications or herbal medications that has a considerable effect on metabolism of AED:s.
  • The patient uses herbal medicine which can interact with AED or Ketogenic diet.
Both
2 Years to 15 Years
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT00552526
Ketogenic diet, EudraCT:2006-001776-20
Yes
Rikshospitalet-Radiumhospitalet HF (Bjorn Bjurulf), Rikshospitalet-Radiumhospitalet HF
Oslo University Hospital
Not Provided
Principal Investigator: Bjorn Bjurulf, MD SSE, Nevrological dep., Rikshospitalet University Hospital
Oslo University Hospital
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP